A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Pomalidomide (Primary) ; Dexamethasone; Filgrastim
- Indications Multiple myeloma
- Focus Adverse reactions
- 05 May 2014 New source identified and integrated (M.D. Anderson Cancer Center; 2013-0018).
- 05 Mar 2014 Planned End Date changed from 1 Feb 2021 to 1 Mar 2021 as reported by ClinicalTrials.gov record.
- 05 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.